Stock Groups

Bristol-Myers Squibb Earnings Beat, Revenue Misses In Q4 -Breaking

by Mike Robinson

[ad_1]

© Reuters. Bristol-Myers Squibb Earnings Beat, Revenue Misses In Q4

On Friday, Investing.com reported that the fourth quarter ended with revenue below analysts’ expectations.

Bristol-Myers Squibb reported earnings per share at $1.83 on $11.99B in revenue. Investing.com polled analyst to predict EPS at $1.8 for revenue $12.09B.

Bristol-Myers Squibb shares have increased 2% since the start of the year. However, they are still down 8.4% from their 52-week high of $69.75 on August 23, 2021. They are outperforming the S&P Global 100 which is down 2.77% from the start of the year.

Bristol-Myers Squibb has been following the major earnings of this month’s Healthcare sector

The report by Bristol-Myers Squibb follows an earnings beat reported January 19th by UnitedHealth, who reported EPS at $4.48 for revenue $73.74B. This compares to the forecasts of EPS $4.3 for revenue $72.98B.

J&J had beat expectations on January 25 with fourth quarter EPS of $2.13 on revenue of $24.8B, compared to forecast for EPS of $2.12 on revenue of $25.28B.

You can keep up-to date on the latest earnings reports by visiting Investing.com’s earnings calendar

Disclaimer: Fusion MediaWe remind you that this site does not contain accurate or real-time data. CFDs are stocks, futures, indexes or Forex. The prices of Forex and CFDs are not supplied by exchanges. They are instead provided by market makers. Because prices might not reflect the market, they may be incorrect. This means that prices cannot be considered indicative and are inappropriate for trading. Fusion Media is not responsible for trading losses that may be incurred as a consequence of the use of this data.

Fusion MediaFusion Media and anyone associated with it will not assume any responsibility for losses or damages arising from the use of this information. This includes data including charts and buy/sell signal signals. You should be aware of all the potential risks and expenses associated with trading in the financial market. It is among the most dangerous investment types.

[ad_2]